Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial

BACKGROUND: COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakharian, Atefeh, Barati, Saghar, Mirenayat, Maryam, Rezaei, Mitra, Haseli, Sara, Torkaman, Pooria, Yousefian, Sahar, Dastan, Alireza, jamaati, Hamidreza, Dastan, Farzaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560/
https://www.ncbi.nlm.nih.gov/pubmed/34426106
http://dx.doi.org/10.1016/j.intimp.2021.107961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560/
https://www.ncbi.nlm.nih.gov/pubmed/34426106
http://dx.doi.org/10.1016/j.intimp.2021.107961

Ejemplares similares